Skip to main content
xMedica

NCT07570316ClinicalTrials.gov

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is…

Phase 3230 participants sought35 sites3 countries

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-05-06; recorded start 2026-06-10
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 87 other studies in this databaseCounted from the lead sponsor named in the record (argenx)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 18 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 230 participants (target), run at 35 sites, across 3 countries.

How this score is built
  • Enrolment23/40

    230 participants (target)

  • Site count15/25

    18 sites

  • Country count7/15

    2 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale7/10

    argenx has led 83 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Conditions

  • Graves' Disease
  • Graves Disease

Eligibility

Eligibility
SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF. * Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \>=ULN (upper limit of normal) at screening. * Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \<0.1 mIU/L at screening. * Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening. Exclusion Criteria: * History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter). * History of RAI (radioactive iodine) therapy or received a total thyroidectomy. * T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \<6 weeks before screening. * Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications. * Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment230 participants sought

Sponsor and collaborators

  • argenx Sponsor

Arms and interventions

  • Part A - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part A - placebo PH20 SC PFSPLACEBO_COMPARATOR

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part B - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part B - placebo PH20 SC PFSEXPERIMENTAL

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part C - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period

Interventions

  • Biological Efgartigimod PH20 SC

    Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

  • Other Placebo PH20 SC

    Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

Outcome measures

  1. Primary outcome

    Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A

    Free triiodothyronine: \[fT3\]; free thyroxine: \[fT4\]; ATDs: antithyroid drugs

    Time frame Up to 24 weeks (part A)

  2. Secondary outcome

    Time to becoming euthyroid off ATDs in part A

    ATDs: antithyroid drugs

    Time frame Up to 24 weeks (part A)

  3. Secondary outcome

    Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A

    MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    Time frame Up to 24 weeks (part A)

  4. Secondary outcome

    Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A

    ULN : upper limit of normal; ATDs: antithyroid drugs.

    Time frame Up to 24 weeks (part A)

  5. Secondary outcome

    Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A

    TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs.

    Time frame Up to 24 weeks (part A)

  6. Secondary outcome

    Time to becoming euthyroid off ATDs and TRAb seronegative

    ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies.

    Time frame Up to 24 weeks (part A) + up to 135 weeks

  7. Secondary outcome

    Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)

    ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    Time frame Up to 24 weeks (Part A)

  8. Secondary outcome

    Time to becoming euthyroid

    Time frame Up to 24 weeks (part A) + up to 135 weeks

  9. Secondary outcome

    Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)

    TSH: thyroid-stimulating hormone; LLN: lower limit of normal.

    Time frame Up to 24 weeks (part A)

  10. Secondary outcome

    Percentage of participants who remain euthyroid without ATDs

    ATDs: antithyroid drug

    Time frame Up to 74 weeks (part B)

  11. Secondary outcome

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months

    ATDs: antithyroid drug

    Time frame Up to 74 weeks (part B) + up to 135 weeks

  12. Secondary outcome

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS

    ATDs: antithyroid drug

    Time frame Up to 72 weeks (part C)

  13. Secondary outcome

    Incidence of AEs and SAEs

    AEs: adverse events ; SAEs: serious adverse events.

    Time frame Up to 135 weeks

  14. Secondary outcome

    Change in ThyPRO-39 over time

    The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status.

    Time frame Up to 135 weeks

  15. Secondary outcome

    Change in PROMIS-PF10a over time

    The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.

    Time frame Up to 135 weeks

  16. Secondary outcome

    Efgartigimod serum concentrations over time

    Time frame Up to 24 weeks (part A) + 72 weeks (part C)

  17. Secondary outcome

    Percentage change from baseline in total IgG levels in serum over time

    IgG: immunoglobulin G

    Time frame Up to 98 weeks

  18. Secondary outcome

    Percentage change from baseline in TRAb serum levels over time

    TRAb: anti-TSHR autoantibodies.

    Time frame Up to 135 weeks

  19. Secondary outcome

    Incidence of ADA against efgartigimod in serum

    ADA: antidrug antibody(ies)

    Time frame Up to 24 weeks (part A) + up to 135 weeks

  20. Secondary outcome

    Incidence of antibodies against rHuPH20 in plasma

    rHuPH20: recombinant human hyaluronidase PH20

    Time frame Up to 24 weeks (part A) + Up to 135 weeks

  21. Secondary outcome

    Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma

    NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20.

    Time frame Up to 24 weeks (part A) + up to 135 weeks

Dates

Dates
Start dateJune 10, 2026 (actual)
Primary completionJune 1, 2028 (estimated)
CompletionMay 1, 2030 (estimated)
First postedMay 6, 2026 (actual)
Last updatedNovember 3, 2026
Results postedNot stated in the registry record
Status last verifiedSeptember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

35 sites are recruiting

Georgia

Georgia
FacilityCityState or regionStatus
LLC American Hospital NetworkTbilisiRecruiting
In Vitro Fertilization Center LLCTbilisiRecruiting
LLC Todua ClinicTbilisiRecruiting
New HospitalsTbilisiRecruiting
LTD Israeli-Georgian Medical Research Clinic HealthycoreTbilisiRecruiting

United Kingdom

United Kingdom
FacilityCityState or regionStatus
Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)GatesheadTyne and WearRecruiting

United States

United States
FacilityCityState or regionStatus
Albany Medical College Community EndocrinologyAlbanyNew YorkRecruiting
University of MichiganAnn ArborMichiganRecruiting
Asheville Clinical ResearchAshevilleNorth CarolinaRecruiting
Profound Research LLC at Tri-City Primary CareCarlsbadCaliforniaRecruiting
Research Institute of DallasDallasTexasRecruiting
Metro Detroit Endocrinology CenterDearbornMichiganRecruiting
Frontier Medical Center - Academy of Diabetes Thyroid and EndocrineEl PasoTexasRecruiting
Profound ResearchFarmington HillsMichiganRecruiting
Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park LocationFleming IslandFloridaRecruiting
The Center for Diabetes and Endocrine CareFort LauderdaleFloridaRecruiting
Juno ResearchHoustonTexasRecruiting
Clinic of EndocrinologyHoustonTexasRecruiting
Tekton Research IrvingIrvingTexasRecruiting
University of Florida Jacksonville College of MedicineJacksonvilleFloridaRecruiting
Truman Medical CenterKansas CityMissouriRecruiting
Ilumina Medical Research LLCKissimmeeFloridaRecruiting
Johnson County Clin-Trials, Inc.LenexaKansasRecruiting
Biopharma Informatic, LLCMcAllenTexasRecruiting
Tekton Research - McKinneyMcKinneyTexasRecruiting
Southern Endocrinology Associates PAMesquiteTexasRecruiting
Oceane 7 Medical & Research Center, IncMiamiFloridaRecruiting
Endocrine Associates of West Village PCNew YorkNew YorkRecruiting
Diabetes Associates Medical GroupOrangeCaliforniaRecruiting
Havana Research Institute LLC.PasadenaCaliforniaRecruiting
Pasadena Clinical TrialsPasadenaCaliforniaRecruiting
Wake Internal Medicine ConsultantsRaleighNorth CarolinaRecruiting
San Jose Clinical TrialsSan JoseCaliforniaRecruiting
Consano Clinical ResearchShavano ParkTexasRecruiting
Alliance for Multispecialty Research, LLCWichitaKansasRecruiting

Study documents

No documents are linked in this registry record.

Changes over time

  1. November 3, 2026

    Site added

    3 sites added (35 total)

    3235

  2. October 16, 2026

    Site added

    6 sites added (32 total)

    2632

  3. September 22, 2026

    Site added

    3 sites added (26 total)

    2326

  4. September 17, 2026

    Site added

    1 site added (23 total)

    2223

  5. August 12, 2026

    Site added

    4 sites added (22 total)

    1822